Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 I

Agilent Technologies Inc. today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for... | April 5, 2022

Related Keywords

Sam Raha , Bristol Myers Squibb , Agilent Technologies Inc , European Union , Genomics Group , Agilent Technologies , Nc Stock Exchange , News , Information , Press Release , Agilent , Technologies , Oday , Nnounced , It , Gas , Xpanded , Parking , N , The , European , Union , Or , Its , Hc , Harmdx , Us , Kid , Identifying , Oesophageal , Squamous , Fell , Arcinoma , Atientsa Us00846u1016 ,